498
Participants
Start Date
August 13, 2019
Primary Completion Date
March 31, 2027
Study Completion Date
March 31, 2027
Englumafusp alfa
Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).
Obinutuzumab
"A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa, then in combination with obinutuzumab Q3W (Part I).~A fixed dose of obinutuzumab will be administered up to 7 days prior to the first dose of englumafusp alfa or between Day -3 and -7 (Part II and Part III)."
Glofitamab
A fixed dose of glofitamab will be administered Q3W in combination with englumafusp alfa in Part II and Part III
Tocilizumab
Participants will receive IV tocilizumab as needed to treat cytokine release syndrome (CRS).
RECRUITING
Auckland City Hospital, Cancer and Blood Research, Auckland
RECRUITING
Rigshospitalet, København Ø
RECRUITING
Peter Maccallum Cancer Centre, Melbourne
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
Waikato Hospital - Cancer and Blood Research Trials Unit, Hamilton
RECRUITING
Odense Universitetshospital, Odense C
RECRUITING
Aarhus Universitetshospital Skejby, Aarhus N
RECRUITING
UZ Gent, Ghent
RECRUITING
Istituto Clinico Humanitas, Rozzano
RECRUITING
Irccs Istituto Europeo Di Oncologia (IEO), Milan
RECRUITING
Asst Papa Giovanni Xxiii, Bergamo
RECRUITING
Hospital Univ. 12 de Octubre, Madrid
RECRUITING
Hospital Clinico Universitario Virgen de la Victoria, Málaga
RECRUITING
CHU Montpellier - Saint ELOI, Montpellier
RECRUITING
CHU DE RENNES - CHU Pontchaillou, Rennes
RECRUITING
Pusan National University Hospital, Busan
RECRUITING
CHRU de Lille, Lille
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
Centre Hospitalier Lyon Sud, Pierre-Bénite
RECRUITING
Istituto Nazionale Tumori Irccs Fondazione g. Pascale, Napoli
RECRUITING
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
ACTIVE_NOT_RECRUITING
City of Hope Medical Center, Pasadena
RECRUITING
University of California San Francisco, San Francisco
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
RECRUITING
Beth Israel Medical Center, Boston
RECRUITING
OhioHealth Research Institute, Columbus
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Queen Elizabeth II Health Sciences Centre, Halifax
RECRUITING
Jewish General Hospital, Montreal
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Hospital Duran i Reynals L'Hospitalet, L'Hospitalet de Llobregat
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
RECRUITING
The HOPE Clinical Trials Unit, Leicester
RECRUITING
University College London Hospitals NHS Foundation Trust, London
Hoffmann-La Roche
INDUSTRY